Back to Journals » Drug Design, Development and Therapy » Volume 11

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

Authors Mir F, Kahveci AS, Ibdah JA, Tahan V

Received 22 December 2016

Accepted for publication 3 February 2017

Published 23 February 2017 Volume 2017:11 Pages 497—502


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Sukesh Voruganti

Video abstract presented by Fazia Mir

Views: 6421

Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan

Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA

Abstract: Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes. Patients reported improvements in general health, fatigue, and emotional and mental well-being after completing combination therapy. The combination treatment is effective, but does need to be administered with caution in patients receiving certain medications or with certain diseases. Herein, we review the safety and efficacy of sofosbuvir/velpatasvir combination regimen for all HCV genotypes.

Keywords: sofosbuvir, velpatasvir, hepatitis C, treatment, pan-genotypic, genotype

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]